Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Perrigo Co. Plc (0Y5E.L)
Dublin, IE
Perrigo Company plc provides over-the-counter health and wellness solutions in the United States, Europe, and internationally. The company operates through Consumer Self-Care Americas and Consumer Self-Care International segments. It offers upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and oral electrolyte beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers. The company also offers healthy lifestyle products, such as smoking cessation and well-being products; skin care products consisting of dermatological care, scar management, lice treatment, and other products for various skin conditions; women's health products comprising feminine hygiene and contraceptives; vitamins, minerals, and supplements; and other miscellaneous self-care products. It sells its products under the Compeed, Dr. Fresh, Firefly, Good Sense, Good Start, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, Steripod, Opill, Solpadeine, Coldrex, Physiomer, NiQuitin, ACO, ellaOne, and Compeed brands. The company also offers contract manufacturing services. It sells its products through retail drug, supermarket, and mass merchandise chains; e-commerce stores; wholesalers; pharmacies; drug and grocery retailers; and para-pharmacies. The company was formerly known as Perrigo Company and changed its name to Perrigo Company plc in December 2013. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 4 Rev. Ana. 1 EPS Ana. |
Dec 2027 4 Rev. Ana. 1 EPS Ana. |
Dec 2028 2 Rev. Ana. 1 EPS Ana. |
Dec 2029 3 Rev. Ana. 1 EPS Ana. |
Dec 2030 3 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
5.27B
est: 4.17B (+26.3%)
|
5.28B
est: 5.63B (-6.3%)
|
4.94B
est: 4.90B (+0.9%)
|
4.73B
est: 4.72B (+0.3%)
|
4.84B
est: 4.80B (+0.8%)
|
4.09B
est: 5.09B (-19.7%)
|
4.14B
est: 4.13B (+0.2%)
|
4.45B
est: 4.51B (-1.4%)
|
4.66B
est: 4.67B (-0.4%)
|
4.37B
est: 4.43B (-1.3%)
|
4.25B
est: 4.25B (+0.2%)
|
4.05B
4.01B – 4.07B
-4.6% YoY
|
4.09B
4.03B – 4.12B
+0.9% YoY
|
4.15B
4.11B – 4.18B
+1.6% YoY
|
4.10B
4.06B – 4.13B
-1.2% YoY
|
4.13B
4.08B – 4.16B
+0.6% YoY
|
| EBITDA |
1.07B
est: 489.41M (+118.1%)
|
1.12B
est: 94.96M (+1,078.2%)
|
1.14B
est: -4.13B (+127.5%)
|
906.00M
est: 534.46M (+69.5%)
|
612.90M
est: 605.87M (+1.2%)
|
526.50M
est: 504.91M (+4.3%)
|
915.60M
est: 515.84M (+77.5%)
|
507.20M
est: 526.88M (-3.7%)
|
646.20M
est: 532.14M (+21.4%)
|
493.70M
est: 661.00M (-25.3%)
|
681.60M
est: 634.28M (+7.5%)
|
605.14M
599.43M – 607.79M
-4.6% YoY
|
610.60M
602.77M – 616.05M
+0.9% YoY
|
620.36M
613.46M – 624.49M
+1.6% YoY
|
613.13M
606.31M – 617.21M
-1.2% YoY
|
616.87M
610.00M – 620.97M
+0.6% YoY
|
| EBIT |
735.30M
est: 157.88M (+365.7%)
|
661.90M
est: 67.82M (+876.0%)
|
692.50M
est: -1.79B (+138.6%)
|
482.40M
est: 445.63M (+8.3%)
|
216.40M
est: 240.80M (-10.1%)
|
141.70M
est: 219.24M (-35.4%)
|
603.40M
est: 223.98M (+169.4%)
|
168.60M
est: 228.78M (-26.3%)
|
286.70M
est: 231.06M (+24.1%)
|
167.80M
est: 322.49M (-48.0%)
|
344.10M
est: 309.45M (+11.2%)
|
295.23M
292.45M – 296.53M
-4.6% YoY
|
297.90M
294.08M – 300.55M
+0.9% YoY
|
302.66M
299.29M – 304.68M
+1.6% YoY
|
299.13M
295.80M – 301.12M
-1.2% YoY
|
300.96M
297.60M – 302.96M
+0.6% YoY
|
| Net Income |
85.00M
est: 862.34M (-90.1%)
|
-4.01B
est: 43.21M (-9,386.3%)
|
119.60M
est: -3.59B (+103.3%)
|
131.00M
est: 115.11M (+13.8%)
|
146.10M
est: 133.66M (+9.3%)
|
-162.60M
est: 156.55M (-203.9%)
|
-116.40M
est: 159.94M (-172.8%)
|
-140.60M
est: 163.36M (-186.1%)
|
-12.70M
est: 165.00M (-107.7%)
|
-171.80M
est: 353.53M (-148.6%)
|
-1.43B
est: 383.94M (-471.3%)
|
293.21M
288.97M – 295.75M
-23.6% YoY
|
327.71M
322.97M – 330.55M
+11.8% YoY
|
370.49M
365.12M – 373.69M
+13.1% YoY
|
389.19M
383.55M – 392.55M
+5.0% YoY
|
401.65M
395.83M – 405.12M
+3.2% YoY
|
| SGA |
1.36B
est: 1.12B (+21.8%)
|
1.21B
est: 692.00M (+74.5%)
|
1.15B
est: 1.08B (+6.2%)
|
1.13B
est: 1.10B (+2.0%)
|
1.15B
est: 1.15B (+0.2%)
|
1.11B
est: 1.23B (-10.0%)
|
1.07B
est: 1.26B (-15.0%)
|
1.16B
est: 1.29B (-9.6%)
|
1.27B
est: 1.30B (-1.9%)
|
1.11B
est: 1.15B (-3.0%)
|
1.06B
est: 1.10B (-4.1%)
|
1.05B
1.04B – 1.05B
-4.6% YoY
|
1.06B
1.05B – 1.07B
+0.9% YoY
|
1.08B
1.06B – 1.08B
+1.6% YoY
|
1.06B
1.05B – 1.07B
-1.2% YoY
|
1.07B
1.06B – 1.08B
+0.6% YoY
|
| EPS |
0.58
est: 6.28 (-90.8%)
|
-28.00
est: 7.12 (-493.5%)
|
0.84
est: 4.90 (-82.9%)
|
0.95
est: 4.55 (-79.1%)
|
1.07
est: 4.03 (-73.4%)
|
-1.19
est: 4.10 (-129.0%)
|
-0.87
est: 2.03 (-142.9%)
|
-1.05
est: 2.04 (-151.5%)
|
-0.03
est: 2.57 (-101.3%)
|
-1.25
est: 2.56 (-148.8%)
|
-10.29
est: 2.77 (-471.2%)
|
2.12
2.09 – 2.14
-23.6% YoY
|
2.37
2.33 – 2.39
+11.8% YoY
|
2.68
2.64 – 2.70
+13.1% YoY
|
2.81
2.77 – 2.83
+5.0% YoY
|
2.90
2.86 – 2.93
+3.2% YoY
|
Owner Earnings
Owner's Earnings history not available.
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Global X Superdividend UCITS ETF USD SDIP.L | 0.93% | 8.40M | 0.45% |
| 2 | Federated Hermes MDT Small Cap Core ETF FSCC | 0.40% | 662.6K | 0.51% |
| 3 | iShares U.S. Pharmaceuticals ETF IHE | 0.32% | 4.27M | 0.38% |
| 4 | iShares S&P Small-Cap 600 Value ETF IJS | 0.15% | 12.34M | 0.18% |
| 5 | Invesco S&P SmallCap 600 UCITS ETF USML.L | 0.10% | 398.5K | 0.14% |
| 6 | iShares Russell 2000 Value ETF IWN | 0.09% | 13.35M | 0.24% |
| 7 | Avantis Global Small Cap Value UCITS ETF AVGS.L | 0.09% | 998.0K | 0.39% |
| 8 | Franklin U.S. Small Cap Multifactor Index ETF FLQS | 0.08% | 43.8K | 0.35% |
| 9 | iShares S&P SmallCap 600 UCITS ETF IDP6.L | 0.08% | 2.57M | 0.30% |
| 10 | iShares Core S&P Small-Cap ETF IJR | 0.08% | 84.98M | 0.06% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive team data is not available for this company yet.
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 0Y5E.L
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
